Steve Ryder

WORK HISTORY

EDUCATION

SKILLS

ABOUT STEVE RYDER

Pharmaceutical R&D executive with broad experience at the highest levels of global development leadership. During the past 30+ years, he has been centrally involved in the global development of many products. In January 2019 he joins RallyBio, a start-up biotechnology firm dedicated to identify and accelerate the development of transformative therapies for patients with severe and rare disorders. Prior to this, he was SVP, Chief Development Officer at Alexion Pharmaceuticals, a biotechnology company dedicated to transforming the lives of patients with rare and ultra-rare devastating diseases. Responsibilities included the global development, registration, and approval of new biological/drug candidates and building the organization that sustains these activities. Prior to Alexion, he was founding President, Astellas Pharma Global Development, leading over staff in Japan (Tokyo), the US (Northbrook IL), and the EU (Leiden, Netherlands) and reporting directly to the CEO of Astellas Pharma, Inc. Recent approvals include Ultomiris™ for the treatment of PNH (US \'18), Soliris™ for the treatment of refractory generalized myasthenia gravis (EU/US/Japan \'17), Strensiq™ for the ultra-rare disease of hypophosphatasia (Japan/US/EU ’15), and Betanis/Myrbetriq™ for OAB (Japan ‘11, US/EU ‘12), the first beta-3 agonist approved for any indication. He is a member of Board of Directors Levo Tx. He is past-President of the American Society of Clinical Pharmacology and Therapeutics, has held leadership positions in the Health Section Governing Board, Regulatory Executive Committee, and Board of BIO and the Science and Regulatory section of PhRMA, is a member of the Clinical Pharmacology Advisory Board of the PhRMA Foundation, and is an active member of several editorial boards. He has served as the industry representative on FDA’s Metabolic/Endocrine Drugs Advisory Committee, and is past-Chairman of the Board of Directors of Gaylord Hospital (Wallingford, CT).